Verastem (NASDAQ:VSTM - Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Verastem to post earnings of ($0.76) per share and revenue of $0.15 million for the quarter.
Verastem Stock Down 3.5 %
NASDAQ VSTM traded down $0.25 during trading on Friday, reaching $6.96. 424,308 shares of the company's stock were exchanged, compared to its average volume of 1,143,632. The firm has a market capitalization of $309.77 million, a PE ratio of -2.18 and a beta of 0.60. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77. Verastem has a fifty-two week low of $2.10 and a fifty-two week high of $13.52. The company's fifty day simple moving average is $5.94 and its 200-day simple moving average is $4.43.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the company. StockNews.com lowered Verastem from a "hold" rating to a "sell" rating in a report on Tuesday, November 19th. BTIG Research lifted their price target on Verastem from $13.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Guggenheim reaffirmed a "buy" rating on shares of Verastem in a research report on Friday, January 24th. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Verastem in a research report on Thursday, December 19th. Finally, Mizuho lifted their price target on Verastem from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Thursday, December 19th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Verastem has an average rating of "Moderate Buy" and an average target price of $13.63.
Check Out Our Latest Report on Verastem
Insiders Place Their Bets
In other news, CEO Dan Paterson sold 8,568 shares of the company's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $5.24, for a total transaction of $44,896.32. Following the transaction, the chief executive officer now owns 347,581 shares of the company's stock, valued at $1,821,324.44. This represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 10,367 shares of company stock valued at $53,990. 2.20% of the stock is currently owned by corporate insiders.
Verastem Company Profile
(
Get Free Report)
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
See Also
Before you consider Verastem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verastem wasn't on the list.
While Verastem currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
